CG MedTech posts strong earnings on US sales growth, higher-margin strategy

CG MedTech, a Korea-based company specializing in orthopedic implants, reported improved profitability in the first quarter of 2025, supported by revenue growth in the U.S. and a focus on higher-margin products.

On a standalone basis, the company posted revenue of 6.25 billion won ($4.4 million) and an operating profit of 670 million won, down 1.3 percent and up 289.7 percent from the same period last year.

The company also posted a net profit of 2.1 billion won, resulting in a return to profitability from a net loss of 943.7 million won reported during the first quarter of last year.

On a consolidated basis, revenue rose 40.8 percent to 11.76 billion won, while reporting operating and net profit of 590 million won and 518.9 million won, resulting in a return to profitability.

Sales in the U.S. were a key contributor. Standalone revenue from the U.S. reached 1.42 billion won, up 25.6 percent from the previous year. The company cited growth in hospital orders and new client accounts for its 3D-printed cervical cage product, “Unispace,” which has received positive feedback from U.S. clinicians.

The company stressed it is continuing its overseas market expansion strategy, including participation in international spine and orthopedic conferences and cadaver workshops, as well as expanded educational efforts targeting healthcare professionals.

In addition, CG MedTech is planning to expand into the dental implant sector, following its acquisition of digital dentistry firm GDS last year. It aims to apply its existing orthopedic and spinal implant technologies to its dental business.

“Our growth is supported by a focus on profitability and global market engagement,” CG MedTech CEO Yu Hyun-seung said. “We will continue to pursue opportunities across product segments and regions, while working with our parent company, CGBio, to enhance R&D and global expansion.”